Treatment of Infections Caused By Antimicrobial-Resistant Gram-Positive Bacteria

被引:16
作者
Kinney, Karen K. [1 ]
机构
[1] Univ Oklahoma, Coll Med, Infect Dis Sect, Dept Med, Oklahoma City, OK 73190 USA
关键词
MRSA; hVISA; VRE; Resistance; Treatment; STAPHYLOCOCCUS-AUREUS BACTEREMIA; SKIN-STRUCTURE INFECTIONS; MINIMUM INHIBITORY CONCENTRATION; IN-VITRO ACTIVITY; DOUBLE-BLIND; METHICILLIN-RESISTANT; VANCOMYCIN-INTERMEDIATE; REDUCED SUSCEPTIBILITY; COMPLICATED SKIN; UNITED-STATES;
D O I
10.1097/MAJ.0b013e3181e99aa4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
An increasing proportion of Staphylococcus aureus infections are caused by methicillin-resistant S aureus. Treatment of infections caused by this organism is challenging, especially because therapy with vancomycin, the traditional antibiotic of choice for methicillin-resistant S aureus infections, is associated with an increasing frequency of treatment failure, and vancomycin insensitive and vancomycin-resistant strains have emerged. In addition, Enterococcus sp. isolated from human infections are increasingly resistant to multiple antimicrobial agents. Newer drugs available for treatment of resistant Gram-positive bacterial infections in the United States include linezolid, daptomycin, tigecycline and telavancin. The precise role for these newer agents is still evolving. Organisms resistant to each of these antimicrobials have emerged. New drugs in development include cephalosporins and carbapenems with MRSA activity.
引用
收藏
页码:209 / 217
页数:9
相关论文
共 110 条
[1]   Meticillin-resistant Staphylococcus aureus among US prisoners and military personnel:: review and recommendations for future studies [J].
Aiello, AE ;
D Lowy, F ;
Wright, LN ;
Larson, EL .
LANCET INFECTIOUS DISEASES, 2006, 6 (06) :335-341
[2]   Quinupristin/dalfopristin: A therapeutic review [J].
Allington, DR ;
Rivey, MP .
CLINICAL THERAPEUTICS, 2001, 23 (01) :24-+
[3]   Management of multidrug-resistant enterococcal infections [J].
Arias, C. A. ;
Contreras, G. A. ;
Murray, B. E. .
CLINICAL MICROBIOLOGY AND INFECTION, 2010, 16 (06) :555-562
[4]   The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: Analysis of pooled clinical trial data [J].
Babinchak, T ;
Ellis-Grosse, E ;
Dartois, N ;
Rose, GM ;
Loh, E .
CLINICAL INFECTIOUS DISEASES, 2005, 41 :S354-S367
[5]   Ceftobiprole: a novel cephalosporin with activity against Gram-positive and Gram-negative pathogens, including methicillin-resistant Staphylococcus aureus (MRSA) [J].
Barboura, April ;
Schmidt, Stephan ;
Rand, Kenneth H. ;
Derendorf, Hartmut .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2009, 34 (01) :1-7
[6]   Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin [J].
Bergallo, Carlos ;
Jasovich, Abet ;
Teglia, Osvaldo ;
Eugenia Oliva, Maria ;
Lentnek, Arnold ;
de Wouters, Luisa ;
Zlocowski, Juan Carlos ;
Dukart, Gary ;
Cooper, Angel ;
Mallick, Rajiv .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2009, 63 (01) :52-61
[7]   Daptomycin Versus Other Antimicrobial Agents for the Treatment of Skin and Soft Tissue Infections: A Meta-Analysis [J].
Bliziotis, Ioannis A. ;
Plessa, Eleni ;
Peppas, George ;
Falagas, Matthew E. .
ANNALS OF PHARMACOTHERAPY, 2010, 44 (01) :97-106
[8]   Daptomycin: Another novel agent for treating infections due to drug-resistant gram-positive pathogens [J].
Carpenter, CF ;
Chambers, HF .
CLINICAL INFECTIOUS DISEASES, 2004, 38 (07) :994-1000
[9]   Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene [J].
Chang, S ;
Sievert, DM ;
Hageman, JC ;
Boulton, ML ;
Tenover, FC ;
Downes, FP ;
Shah, S ;
Rudrik, JT ;
Pupp, GR ;
Brown, WJ ;
Cardo, D ;
Fridkin, SK .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (14) :1342-1347
[10]   Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus [J].
Charles, PGP ;
Ward, PB ;
Johnson, PDR ;
Howden, BP ;
Grayson, ML .
CLINICAL INFECTIOUS DISEASES, 2004, 38 (03) :448-451